535 layoffs tied to Dexcom’s manufacturing move

Today’s Big News

Jul 1, 2024

Fierce Biotech's Quarterly IPO and M&A Roundup: Q2'24


BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival


Growing pains: Dexcom’s manufacturing move to lay off 535 in San Diego


As former BMS CEO Giovanni Caforio plots move to Novartis, will noncompete issues come into play?


Talc claimants denied in effort to block Johnson & Johnson's latest Texas two-step bankruptcy


FDA elevates ventilator recalls from Philips, Baxter, Zoll

 

Featured

Fierce Biotech's Quarterly IPO and M&A Roundup: Q2'24

The slow quarter follows an exciting first one, in which pharma finally spent some of the trillions in cash hanging around for such transactions.
 

Top Stories

BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

Bristol Myers Squibb is walking away from its $650 million bet on an Eisai antibody-drug conjugate (ADC). The Japanese drugmaker said BMS decided to end the co-development agreement as part of an ongoing portfolio prioritization push.

Growing pains: Dexcom’s manufacturing move to lay off 535 in San Diego

First reported by The San Diego Union-Tribune, the diabetes sensor maker said it plans to transition its HQ into an innovation center after previously housing commercial production and R&D.

As former BMS CEO Giovanni Caforio plots move to Novartis, will noncompete issues come into play?

Novartis recently said it will propose Bristol Myers Squibb's former chairman and CEO, Giovanni Caforio, to serve as its next board chair in 2025. Fierce Pharma explored the status of the industry's noncompete clauses with experts to learn whether an intercompany transition at the highest levels can proceed without a hitch.

Talc claimants denied in effort to block Johnson & Johnson's latest Texas two-step bankruptcy

Less than three weeks after a group of cancer victims filed a motion attempting to block Johnson & Johnson's latest talc litigation bankruptcy plan—which comes with a $6.5 billion class-action settlement offer—a New Jersey federal court has quashed the effort.

FDA elevates ventilator recalls from Philips, Baxter, Zoll

Issues with ventilators across three major manufacturers—Philips, Baxter and Zoll—have led to a string of Class I recall notices from the FDA, the agency’s most severe level.

UniQure sells gene therapy manufacturing site to Genezen, along with production of CSL's Hemgenix

UniQure has sold its commercial viral vector manufacturing facility in Lexington, Mass., to Genezen, which will now supply uniQure’s clinical portfolio and produce CSL Behring’s hemophilia B gene therapy Hemgenix from the site.

J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party

Johnson & Johnson has presented phase 3 data on nipocalimab in generalized myasthenia gravis, providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB.

FDA commissioner heralds end to US shortfall of chemo drug cisplatin

Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said.

Lilly signs $140M upfront partnership with Radionetics in latest radiopharma play

Eli Lilly is continuing to pursue its newfound passion for radiopharmaceuticals, this time handing Radionetics Oncology $140 million in upfront cash to partner on its pipeline of G protein-coupled receptor (GPCR) targeted drugs.

Eli Lilly expands ‘Get Better’ ad campaign to cover skin disease health equity

Eli Lilly has expanded its “Get Better” campaign, rolling out ads focused on its work to address inequities in access to dermatology diagnosis and treatment.
 
Fierce podcasts

Don’t miss an episode

The best biopharma M&A deals 

In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years.  
 

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.
Whitepaper

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry.  Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.
eBook

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.
 

Industry Events

On Helix

Date: ‌4 ‌July ‌2024 ‌- ‌Location: ‌Babraham ‌Research ‌Campus, ‌Cambridge ‌UK

 

Upcoming Fierce Events